Access cutting-edge epidermolysis bullosa simplex treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access epidermolysis bullosa simplex specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related epidermolysis bullosa simplex treatment provided free
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Sponsor: TWi Biotechnology, Inc.
Check if you qualify for this epidermolysis bullosa simplex clinical trial in Chicago, IL
If you're searching for epidermolysis bullosa simplex treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced epidermolysis bullosa simplex specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.